Ciprofloxacin for the Prevention of Meningococcal Meningitis 2018
Meningitis, Meningococcal
About this trial
This is an interventional prevention trial for Meningitis, Meningococcal
Eligibility Criteria
Inclusion Criteria:
- Resident in a village included in the study area
Exclusion Criteria:
- Patients currently exhibiting symptoms of meningitis (to be immediately referred for further care)
- Persons with a known allergy to fluoroquinolone antibiotics.
Sites / Locations
- Madarounfa Health District
Arms of the Study
Arm 1
Arm 2
Arm 3
No Intervention
Active Comparator
Active Comparator
Standard care
Household prophylaxis arm
Community prophylaxis arm
No chemoprevention for contacts of cases of meningitis (current standard of care) with a health promotion visit by a study nurse after the first notification of cases during the epidemic
Chemoprophylaxis with a single dose of oral ciprofloxacin for household members of reported cases of meningitis. For participants age >12 years: 500 mg tablet; age 5-12 years: 250 mg tablet; age 1-4 years: 125 mg tablet; age 3-11 months: 100 mg (2 ml oral suspension); age <3 months: 75 mg (1.5 ml oral suspension)
Chemoprophylaxis with ciprofloxacin in the setting of a village-wide distribution after the notification of the first case of meningitis in a village. For participants age >12 years: 500 mg tablet; age 5-12 years: 250 mg tablet; age 1-4 years: 125 mg tablet; age 3-11 months: 100 mg (2 ml oral suspension); age <3 months: 75 mg (1.5 ml oral suspension)